Pulmonologist call reinforces Stifel view of upside for Insmed

After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a “bolus” of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it “remains early days in the launch,” the call with the doctors reinforced his belief that Insmed’s Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.

https://thefly.com/landingPageNews.php?id=2884219